Post hoc analyses of 2 phase 3 clinical trials assessing efficacy and safety of ranibizumab in patients with branch RVO ( Ranibizumab for the Treatment of Macular Edema following Branch Retinal Vein Occlusion : Evaluation of Efficacy and Safety [ BRAVO ] study ; NCT00061594 ) and central RVO ( Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein Occlusion Study : Evaluation of Efficacy and Safety [ CRUISE ] ; NCT00056836 ) over 12 months .